Genfit S.A. (EPA:GNFT)
France · Delayed Price · Currency is EUR 8.28
+0.08 (0.98%)
Apr 24, 2026, 4:54 PM CET
Genfit Revenue
In the year 2025, Genfit had annual revenue of 65.43M EUR, down -7.44%. Genfit had revenue of 29.90M in the half year ending December 31, 2025, with 54.34% growth.
Revenue
65.43M
Revenue Growth
-7.44%
P/S Ratio
6.24
Revenue / Employee
348.05K
Employees
188
Market Cap
408.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.43M | -5.26M | -7.44% |
| Dec 31, 2024 | 70.69M | 36.21M | 105.01% |
| Dec 31, 2023 | 34.48M | 8.24M | 31.38% |
| Dec 31, 2022 | 26.25M | -59.11M | -69.25% |
| Dec 31, 2021 | 85.36M | 76.67M | 883.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 174.66M |
| Cellectis | 67.79M |
| Nanobiotix | 32.59M |
| MedinCell | 32.44M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
| Sensorion | 5.81M |
Genfit News
- 3 days ago - GENFIT: Publication of the 2026 Extra-Financial Report (fiscal year 2025) - GlobeNewsWire
- 21 days ago - GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF - GlobeNewsWire
- 2 months ago - GENFIT to receive US$20M milestone after Ipsen's Iqirvo® exceeds the US$200M threshold in its first full year of net sales - GlobeNewsWire
- 3 months ago - GENFIT Announces 2026 Financial Calendar - GlobeNewsWire
- 4 months ago - GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy - GlobeNewsWire
- 5 months ago - GENFIT Announces Appointment of new Chief Medical Officer - GlobeNewsWire
- 5 months ago - GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update - GlobeNewsWire